{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:01:40Z","timestamp":1788566500623,"version":"build-2803163510"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"(Ministrelli Program for Urology Research and Education-MPURE)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2017,2]]},"abstract":"\n Aims<\/jats:title>\n To explore factors that may predispose patients to reoperation after sacral neuromodulation (SNM).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients enrolled in our longitudinal neuromodulation database were reviewed. Medical records data, and voiding diaries, Interstitial Cystitis Symptom\u2013Problem Indices (ICSI\u2010PI), and Overactive Bladder Questionnaires (OAB\u2010q) at baseline and 3 months were analyzed with Pearson's \u03c7\n 2<\/jats:sup>\n , Fisher's Exact test, Wilcoxon rank tests, and multivariable logistic regression.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 407 patients, 134 (33%) had at least one reoperation over median 28.9 months follow\u2010up (range 1.6\u2013121.7); 78\/407 (19%) were revised, and 56\/407 (14%) were explanted. The most common reason for reoperation was lack of efficacy\/worsening symptoms (n\u2009=\u200987). The reoperations group had a higher proportion of women (\n P<\/jats:italic>\n \u2009=\u20090.049), lower mean body mass index (BMI;\n P<\/jats:italic>\n \u2009=\u20090.010), more reprogramming events (\n P<\/jats:italic>\n \u2009<\u20090.0001), longer median follow\u2010up (\n P<\/jats:italic>\n \u2009=\u20090.0008), and higher proportions with interstitial cystitis (\n P<\/jats:italic>\n \u2009=\u20090.013), using hormone replacement therapy (\n P<\/jats:italic>\n \u2009=\u20090.0004), and complications (\n P<\/jats:italic>\n \u2009<\u20090.0001). Both reoperations\/no reoperations groups had similar improvements in ICSI\u2010PI (\n P<\/jats:italic>\n \u2009<\u20090.0001 for both), OAB\u2010q severity (\n P<\/jats:italic>\n \u2009<\u20090.0001 for both) and quality of life (\n P<\/jats:italic>\n \u2009<\u20090.0001 for both). On multivariate analysis, only longer follow\u2010up (\n P<\/jats:italic>\n \u2009=\u20090.0011; OR 1.048; CI 1.019, 1.078) and having a complication (\n P<\/jats:italic>\n \u2009<\u20090.0001; OR 23.2; CI 11.47, 46.75) were significant predictors of reoperations. In women only, using HRT at time of implant was also predictive of reoperation (\n P<\/jats:italic>\n \u2009=\u20090.0027; OR 3.09; CI 1.48, 6.46).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In this largest known series to date, one third of the patients required reoperation and the most common reason was lack of efficacy\/worsening symptoms. Ongoing study is needed as the technology continues to evolve.\n Neurourol. Urodynam. 36:354\u2013359, 2017<\/jats:italic>\n . \u00a9 2015 Wiley Periodicals, Inc.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/nau.22929","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T11:01:16Z","timestamp":1448017276000},"page":"354-359","source":"Crossref","is-referenced-by-count":40,"title":["Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients"],"prefix":"10.1002","volume":"36","author":[{"given":"Kenneth M.","family":"Peters","sequence":"first","affiliation":[{"name":"Beaumont Health System Royal Oak Michigan"},{"name":"Oakland University William Beaumont School of Medicine Rochester Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Killinger","sequence":"additional","affiliation":[{"name":"Beaumont Health System Royal Oak Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P.","family":"Gilleran","sequence":"additional","affiliation":[{"name":"Beaumont Health System Royal Oak Michigan"},{"name":"Oakland University William Beaumont School of Medicine Rochester Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Bartley","sequence":"additional","affiliation":[{"name":"Beaumont Health System Royal Oak Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Wolfert","sequence":"additional","affiliation":[{"name":"Beaumont Health System Royal Oak Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Boura","sequence":"additional","affiliation":[{"name":"Beaumont Health System Royal Oak Michigan"},{"name":"Oakland University William Beaumont School of Medicine Rochester Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.06.142"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.11.047"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80333-1"},{"key":"e_1_2_7_5_1","unstructured":"CoyneKS LaiJS ZyczynskiT et al. An overactive bladder symptom and quality\u2010of\u2010life short form: Development of the Overactive Bladder Questionnaire (OAB\u2010q) short form (SF). Presented at the Joint Meeting of the International Continence Society and the International Urogynecological Association; August 23\u201327 2004; Paris France."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00597-5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.03.020"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07426.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.10.054"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPV.0b013e31828ab3c9"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22707"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22294"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-011-1512-2"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.0001-6349.2004.00581.x","article-title":"A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder","volume":"83","author":"Cardoza L","year":"2004","journal-title":"Acta Obstet Gynecol Scand"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22929","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T02:28:31Z","timestamp":1696386511000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1002\/nau.22929"],"URL":"https:\/\/doi.org\/10.1002\/nau.22929","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,20]]}}}